Qube Research & Technologies (QRT)
CPRX

Qube Research & Technologies (QRT)’s Catalyst Pharmaceutical CPRX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.9M Buy
2,254,355
+1,841,689
+446% +$54.4M 0.07% 385
2026
Q1 		$10.2M Sell
412,666
-74,469
-15% -$1.77M 0.01% 1267
2025
Q4 		$11.4M Sell
487,135
-334,067
-41% -$7.44M 0.01% 1264
2025
Q3 		$16.2M Sell
821,202
-193,208
-19% -$3.97M 0.02% 1013
2025
Q2 		$22M Buy
1,014,410
+254,114
+33% +$6M 0.02% 826
2025
Q1 		$18.4M Buy
760,296
+101,044
+15% +$2.28M 0.02% 790
2024
Q4 		$13.8M Sell
659,252
-7,988
-1% -$172K 0.02% 904
2024
Q3 		$13.3M Buy
667,240
+538,506
+418% +$9.98M 0.02% 868
2024
Q2 		$1.99M Buy
128,734
+38,484
+43% +$599K ﹤0.01% 1627
2024
Q1 		$1.44M Buy
+90,250
New +$1.36M ﹤0.01% 1934
2023
Q4 		– Sell
-64,578
Closed -$755K – 4398
2023
Q3 		$755K Buy
+64,578
New +$864K ﹤0.01% 1855
2023
Q1 		– Sell
-121,873
Closed -$2.27M – 2599
2022
Q4 		$2.27M Buy
+121,873
New +$1.88M 0.01% 899
2022
Q3 		– Sell
-122,638
Closed -$860K – 2566
2022
Q2 		$860K Sell
122,638
-31,071
-20% -$228K 0.01% 1164
2022
Q1 		$1.27M Sell
153,709
-24,611
-14% -$174K 0.01% 1043
2021
Q4 		$1.21M Buy
178,320
+93,818
+111% +$617K 0.01% 1078
2021
Q3 		$448K Buy
84,502
+40,238
+91% +$220K 0.01% 1269
2021
Q2 		$255K Buy
+44,264
New +$228K ﹤0.01% 1667
2020
Q2 		– Sell
-34,024
Closed -$131K – 1745
2020
Q1 		$131K Buy
+34,024
New +$140K 0.01% 930

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CPRX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Catalyst Pharmaceutical (CPRX) stake by 446% in Q2 2026, buying an estimated $54.4M and bringing the position to 2,254,355 shares worth $70.9M. The position accounts for 0.07% of the portfolio, ranked #385.

Qube Research & Technologies (QRT) first reported a position in CPRX in Q1 2020 and has held it in 18 quarters since. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Qube Research & Technologies (QRT) held 2,254,355 shares of Catalyst Pharmaceutical worth $70.9M as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 1,841,689 Catalyst Pharmaceutical shares in Q2 2026, an estimated $54.4M.
  • Catalyst Pharmaceutical made up 0.07% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #385 holding.
  • Qube Research & Technologies (QRT) first reported a position in Catalyst Pharmaceutical in Q1 2020 and has held it in 18 quarters since.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.